
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
Biosimilars are gaining acceptance, and with oncology drugs exceeding 80% adoption, biosimilars in the US are saving the health care system $13 billion to $15 billion annually, according to Shreehas P. Tambe, MD, managing director and CEO at Biocon …